It would be possible to more accurately identify high-risk patients using baseline myostatin levels in patients who have similar residual liver functions or HCC risks based on other methods, which would thereby guide physicians to plan surveillance strategies for patients at risk of developing HCC. The gene discussed is MSTN; the disease is hepatocellular carcinoma.